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Effects on insulin-like growth factor I on renal function in normal men.
Acute and chronic studies in rats have shown that administration of
human recombinant insulin-like growth factor I (rhIGF-I) lowers renal
vascular resistance and increases RPF, GFR and proximal tubular
phosphate absorption. In the present study we examined the effects of
subcutaneous injections of rhIGF-I on glomerular and tubular function
in eight normal men. Individuals were studied for 5.5 consecutive days
in a clinical research center while they ate a constant diet. Four subjects
were studied in a non-volume expanded state (Group 1) and four
individuals were evaluated during a saline load. From the second to the
fourth day, subjects received subcutaneous injections of rhIGF-I, 60
gIkg, at 0800, 1400 and 2000 hours. After commencing the rhIGF-I
injections, serum IGF-I levels rose quickly and remained at about three
to four times that of baseline throughout the period of rhIGF-I injec-
tions. In both the normal and the saline loaded subjects, renal vascular
resistance decreased and RPF and GFR (PAH and inulin clearances)
rose quickly and were clearly altered within six hours after starting the
rhIGF-I injections. RPF had increased by 32 3% and 33 2% (grand
mean 5EM) in the normal and the saline loaded subjects, and GFR
rose by 22 3% and 36 4% in the two groups. In both groups the
absolute and the fractional excretion of phosphate decreased markedly
during rhIGF-I treatment, but the absolute and fractional excretion of
calcium did not change. The urinary fractional and absolute excretion of
albumin and IgG also increased, although slightly, with rhIGF-I injec-
tions. There was no consistent effect of IGF-I on tubular sodium
handling. These findings demonstrate that in normal men subcutaneous
injections of rhIGF-I greatly increase RPF, GFR, and tubular phospho-
rus reabsorption and enhances microproteinuria.
Insulin-like growth factor I (IGF-I) is a peptide growth factor
that is present in plasma and most tissues. In the rat, IGF-I is
particularly abundant in the liver and kidneys [1, 2]. IGF-I is
synthesized in the kidney and released from the glomerulus, but
large amounts are found in cortical collecting duct cells [3—6].
Previous studies that we performed in normal human subjects
injected with recombinant human growth hormone suggested
that IGF-I may mediate the growth hormone induced rise in
renal plasma flow (RPF) and glomerular filtration rate (GFR)
[7]. This relationship was therefore examined in further detail in
rats where we demonstrated that a short-term infusion of
rhIGF-I increases RPF and GFR [81. Further research in rats
indicated that rhIGF-I also increased single nephron plasma
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flow and GFR, and that these effects were caused by an
increase in the glomerular ultrafiltration coefficient and in RPF
secondary to a reduction in the renal efferent and possibly
afferent arteriolar resistance [9]. Guler and associates reported,
in preliminary studies, that the subcutaneous administration of
rhIGF-I for three days raised the renal clearances of iothala-
mate and iodohippurate [10]. However, their studies were only
conducted in two normal men, and renal function was only
measured before treatment, after three days of rhIGF-I admin-
istration and after cessation of treatment [10]. Guler et al also
showed in two subjects (one of whom was studied in the
previous paper) that rhIGF-I increases the creatinine clearance
[11]. Experimental studies in rats and in isolated tubules have
also shown that IGF-I increases renal tubular phosphate ab-
sorption [12—141. No studies of the effects of rhIGF-I on the
renal tubular reabsorption of phosphorus or calcium have been
reported in humans.
We, therefore, decided to examine the effects of rhIGF-I on
renal physiology in humans in a more systematic manner.
Specifically, the present study was carried out in a substantially
larger cohort of subjects: eight men. We examined the hypoth-
eses that (1.) rhIGF-I increases RPF and GFR using definitive
measurements (para-aminohippurate and inulin clearances),
and that this effect is sustained with repeated rhIGF-I injec-
tions, at least for 3.5 days; (2.) that rhIGF-I increases RPF and
GFR acutely, within hours and (3.) that rhIGF-I will reduce the
fractional excretion of phosphate in humans as it has been
shown to do in isolated rabbit tubules and in intact animals
[12—14]. (4.) Also, we tested whether rhIGF-I will affect the
fractional excretion of calcium, sodium and water and whether
it will enhance microalbuminuria or microglobulinuria. Studies
were performed in healthy adults who were both normally
hydrated and who were undergoing volume expansion with
saline.
Methods
Study protocol
Eight normal men participated in the study; four were as-
signed to each of the two groups described below. All were
found to be healthy based on medical history, a normal physical
examination, and a normal ECG, chest x-ray, CBC, serum
chemistry panel (electrolytes, BUN, creatinine, total, LDL-
and HDL-cholesterol, triglycerides, liver function tests), urinal-
ysis and urinary sediment, and a negative VDRL and urinary
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Table 1. Actual daily energy and protein intakes in both groups of subjects
Day 1
Baseline
Day 2
IGF-I
Day 3
IGF-I
Day 4
IGF-I
Day 5
—
Non-saline loaded subjects (Group 1)
Energy kcal/kga 37.3 2.4 37.5 2.0 36.5 2.3 37.1 1.9 36.8 2.1
Protein(g/kg) 1.11±0.04 1.11±0.04 1.09±0.04 1.10±0.03 1,08±0.04
Saline loaded subjects (Group 2)
Energy kcal/kga 35,6 2.4 35.5 2.4 34.6 2.0 34.3 2.1 32.5 3.4
Protein (g/kg) 1.01 0.06 1.01 0.04 0.97 0.07 0.97 0.07 0.94 0.11
Data are means SEM.
a Includes the energy intake from the intravenous d-glucose
drug screening test. Written informed consent, as approved by
the institutional review board, was obtained from each subject
prior to commencing the study.
Subjects were admitted to the clinical research center at
Harbor-UCLA Medical Center the afternoon before beginning
the 5.5 day study. Throughout the period of the study, subjects
were fed common foods providing protein, 0.8 to 1.2 g/kg/day,
and energy, 30 to 40 kcal/kg/day. In each subject, the total daily
protein and energy intake did not vary by more than 10% from
the mean on any day of the study. The daily protein and energy
intake were each fed in six equal portions each day of study at
the following times: 8:05 a.m., 11:05 a.m., 2:05 p.m., 5:05p.m.,
8:05 p.m., and 11:05 p.m. Each meal was ingested within a 25
minute period. Fluids that contained little or no calories were
allowed ad libitum. Meals were prepared and food intake was
monitored by the nutritional staff at the clinical research center.
The actual daily protein and energy intakes on each day of
study are shown in Table 1. On each day subjects were fasted,
except for drinking water, and the small amount of glucose
infused (see below), from 11:30 p.m. until 8:05 a.m. the next
morning in order to obtain morning blood samples in a post-
absorptive state for the measurement of plasma insulin, gluca-
gon and growth hormone.
On the morning of the first day of study, two intravenous
lines were placed, one in each forearm. A heparin lock was
placed in one line for venous blood sampling; the contralateral
line was used for the continuous intravenous infusions. An
intravenous infusion containing 0.45% saline, 2.5% glucose,
inulin and PAH was begun at 8:30 a.m. on the first day of study
and was continued until termination of the study on the sixth
day. Subjects were divided into two groups of four individuals
based on the volume of the solution infused intravenously. The
mean ages in Group 1 and 2 subjects were 29 2 (5EM) and 28
3 years, respectively. Group 1 subjects received an infusion
rate of 50 mllhr, whereas Group 2 subjects were infused at a rate
of 150 mI/hr to induce and maintain a volume expanded state.
Thus, the Group 1 subjects received during each 24 hours 5.4
g/24 hours of NaC1 and 27 g of d-glucose intravenously, in
addition to the salt supplied by foods and oral fluids. The Group
2 subjects received three times this intravenous load of water
over each 24 hours, 16.2 g of NaC1, and 81 g of d-glucose. The
glucose intake was calculated on the premise that 90% of
glucose in intravenous solutions was anhydrous glucose [15]. In
both groups, the inulin (Laevosan Gesellschaft, LinzfDonau,
Austria) and para-aminohippuric acid (Merck, Sharp and
Dohme, West Point, Pennsylvania, USA) concentrations were
adjusted so as to provide inulin, 1.5 g/hr and PAH, 0.5 g/hr. At
8:00 a.m. and 8:00 p.m., each subject received 300mg of lithium
carbonate orally.
After starting the infusion, 90 minutes were allowed for
equilibration of the clearance markers in the extracellular
space. At 10:00 a.m. on the first day of study, subjects emptied
their bladders by spontaneous voiding. Thereafter, urine was
collected continuously in two hour periods except for one eight
hour period between midnight and 8:00 a.m. the next day. This
schedule of urine collections was continued throughout the
entire study until 12:00 noon on the sixth day of study.
Venous blood was obtained at the beginning and end of each
urine collection period for the measurement of serum sodium,
calcium, phosphate, lithium, glucose, creatinine, albumin, IgG,
inulin and PAH. The same parameters were measured in the
urine collected during each period. The sitting blood pressure
was also measured at the beginning and end of each period.
Every day, additional blood samples were obtained for the
measurement of plasma IGF-I at 8:00 a.m., 2:00p.m., and 8:00
p.m. immediately before each of the rhIGF-I injections was
given.
The first day of study was used as baseline. On days 2, 3, and
4, subjects were given subcutaneous injections of rhIGF-I
(Ciba-Geigy Corporation, Summit, New Jersey, USA), 60
pglkg body weight, at 8:05 a.m., 2:05 p.m. and 8:05 p.m. after
the blood and urine collections had been obtained. The last
injection was administered at 8:05 a.m. at the beginning of day
5. The subjects were then monitored for a further 28 hours
without IGF-I injections. Thus, a total of ten injections of
rhIGF-I was administered to each subject. The injections were
given subcutaneously into the abdominal wall, and the injection
sites were rotated among the four abdominal quadrants.
Laboratory methods
Urinary and serum sodium, lithium, glucose, phosphate,
creatinine, calcium, and serum albumin and IgG were measured
by routine laboratory methods. Inulin and PAH were measured
as previously described [7]. The total plasma IGF-I concentra-
tions were measured with a specific radioimmunoassay using a
commercially available kit (Incstar Corporation, Stillwater,
Minnesota, USA). Plasma was acidified to dissociate IGF-I
from its binding proteins and extracted on ODS-silica extraction
columns. The 50% inhibition point on the calibration curve is at
about 150 ng/ml. The calibration curve is linear (r2 = 0.998)
between 20 and 770 ng/ml. The assay antibody used has been
checked for cross reactivity with IGF-II (<0.01%) and rat-
multiplication stimulating activity (<0.01%). The concentration
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Table 2. Physiological and plasma hormone measurements in the subjects in both groups
Day I
Baseline
Day 2
IGF-I
Day 3
IGF-I
Day 4
IGF-I
Day 5
—
Non-saline loaded subjects (Group I)
MABP mm Hga 96 1 95 1 98 1 97 1 100 1°
Body weight kgb 85.1 7.5 85.1 7.5 85.3 7.4 85.2 7,2 85.3 7.1
Urine flow ml/mina 3.55 0.22 3.13 0.25 2.87 0.22 3.03 0.25 2.86 0.26
Glucose mg/dla 109 2 101 2 107 2 113 4 109 2
Glucagon pg/mi" 78 36 106 50 88 34 90 41 79 31
Insulin ng/mi" 13 3 11 5 8 3 9 5 8 3
Growth hormone ng/ml" 0.5 0.1 0.5 0.1 0.6 0.2 0.5 0.1 0.7 0.2
Saline loaded subjects (Group 2)
MABP mm Hga 86 1 90 IC 91 1° 93 1° 90 ic
Body weight kgb 83.2 6.9 84.0 6.7 84.7 6.8 84.5 6.8 84.5 6.8°
Urine flow ml/mina 3,95 0.42 3,71 0,37 4.60 0.46 4.13 0.46 4.02 0.42
Glucose mg/dF 110 5 107 5 108 3 112 3 114 5
Glucagon pg/mi" 115 49 112 44 89 30 87 26 68 14
Insulin ng/ml" 13 2 18 5 11 3 7 2 10 3
Growth hormone ng/ml" 0.5 0.3 0.6 0.3 0.6 0.4 0.5 0.3 0.4 0.2
Both groups (N = 8)
Glucose mgfdl" 105 2 99 3 101 2 103 2 100 2
Glucagon pg/mi" 101 20 96 27 87 20 79 21 72 16
Insulin ng/ml" 14 2 12 3 8 2° 9 3 9 2
a Grand mean SEM of nine values obtained throughout the day of study; For calculation of the grand mean, the values obtained during the 8
hr overnight collection are given four times the weight of the data obtained from each of the 2 hr collection periods; All other data are means
SEM.
b Mean SEM of values obtained in the fasting state before breakfast, in each subject
P < 0.05 compared to baseline
—24 —12 0 12 24 36 48 60 72 84 96
L baselineJ Time, hours
Fig. 1. Serum IGF-I levels in the 8 subjects. Subcutaneousinjections
with rhIGF-I, 60 pg/kg body wt, were given at 0, 6, 12, 24, 30, 36, 48,
54, 60 and 72 hours immediately after samples for the measurement of
serum IGF-I were obtained. Values are mean 5EM; < 0.05.
of albumin in urine was measured by an enzyme-linked immu-
nosorbent assay (ELISA) using a commercially available kit
(Albuwell, Exocell, Inc., Philadelphia, Pennsylvania, USA).
The urinary IgG concentration was measured with an ELISA
that was adapted from the method described by Fomsgaard et al
with minor modifications [16]. Briefly, 96-well plates were
coated with 100 1.d/well of rabbit anti-human IgG, y-chain
specific (Cappel/Organon Teknika, Durham, North Carolina,
USA), 1:10,000 in coating buffer (0.1 M NaHCO3, pH 9.8) for 72
hours at 4°C. Wells were washed three times with washing
buffer (0.15 M NaC1, 0.02 M NaH2PO4, 0.05% Tween 20, pH
7.3). Respective wells were then incubated in triplicate with 100
ilIwelI of standards (human IgG, 4 to 125 ng/ml; Cappel) or
urines diluted in incubation buffer (PBS containing 1% normal
rabbit serum) for 16 hours at room temperature. After washing
the wells three times, 100 1.d of peroxidase-labeled IgG fraction
of rabbit anti-human IgG, y-chain specific (Cappel), 1:15,000 in
PBS was added to each well for 60 minutes, and plates were
washed another five times. The color reaction was performed
with 100 idIwell of substrate solution, and the reaction was
stopped after 30 minutes with 0.1 M sodium sulfite in 4 N H2S04.
The absorptions of the wells were measured against blank at 492
nm in an ELISA plate reader. The intra- and interassay coeffi-
cients of variation are 8% and 11%, respectively.
Calculations and statistics
For each clearance period, the serum levels measured at the
beginning and end were averaged. Renal clearances were
calculated as the product of urine flow rate and the urine
concentration divided by the serum concentration. The GFR
was calculated as the clearance of inulin; the RPF was calcu-
lated as the clearance of PAH and was corrected for the renal
extraction of PAH that has been estimated by other investiga-
tors to be 0.85 in normal subjects [17, 181. The mean arterial
blood pressure (MABP) was estimated from the systolic and
diastolic readings as MABP = — Pcijas)/3 + 'dias The
renal blood flow (RBF) was calculated as RBF = RPF/(l —
HCT). The total renal vascular resistance (RVR) was calculated
as RVR = MABP/RBF. The fractional excretion of a given
solute was calculated as the clearance of the solute divided by
the clearance of inulin and is expressed as percent of the
glomerular filtration rate. The fractional clearances of IgG and
albumin are calculated as C150/Cjn and CAI,,/CIfl, respectively.
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Fig. 2. Renal plasma flow (RPF) and GFR in
the normal subjects (N = 4) who received the
lesser saline infusion rate. Each vertical bar
represents one clearance period. Arrowso o o o indicate times of subcutaneous injection of
rhIGF-I, 60 pg/kg. The striped horizontal bars
mark the weighed grand mean SEM during
baseline.
Group data are presented as means and standard errors.
When grand means are reported, they are calculated for the
period beginning at 10:00 a.m. until 8:00 a.m. the next day. This
was done because data from the 8:00 to 10:00 a.m. period are
not available on the first day since the concentrations of the
clearance markers had not yet equilibrated. Hence, each day of
study consisted of seven two-hour clearance periods and one
eight-hour clearance period. For the calculations, the eight-
hour clearance period was given four times the weight of any of
the two hour periods. On day six, only two clearance periods
were available (8 to 10 a.m, and 10 to 12 p.m.). Therefore, data
obtained on day 6 have been omitted from statistical compari-
sons.
Statistical analyses were performed using the analysis of
variance and the Newman-Keuls multicomparison test unless
indicated otherwise. A P value of less than 0.05 was considered
to reflect statistical significance. Variance is expressed as the
standard error of the mean.
Results
Effects of exogenous rhIGF-I on plasma chemistries and
other values
In the subjects in Group 1 (lower infusion rate), the mean
arterial pressure did not change from baseline during the days of
rhIGF-I treatment, except that values were slightly but signifi-
cantly higher on the fifth day (Table 2). Body weight and the
urine flow rate were not different on any given day of the study
(Table 2). The subjects in Group 2 underwent volume expan-
sion, as indicated by a significant rise in MABP of 4 mm Hg and
an increase in body weight of 1.3 0.1 kg above the baseline
weight (P < 0.05 by paired t-test with day 5); most of the
A
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Fig. 3. RPF and GFR in the saline volume
loaded normal subjects (N = 4). Each vertical
bar represents one clearance period. Arrows
indicate times of subcutaneous injection of
rhIGF-I, 60 sgIkg. The striped horizontal bars
mark the weighed grand mean SEM during
baseline.
changes in these parameters occurred between Days 1 and 2 of
the study. In each group of subjects, fasting serum glucose and
plasma growth hormone, insulin and glucagon levels did not
change during IGF-I treatment as compared to baseline values
(Table 2). In the two groups of subjects combined, plasma
insulin decreased significantly on the second morning of
rhIGF-I injections (Table 2).
The mean serum IGF-I level rose to almost three times
baseline within six hours after the first rhIGF-I injection, before
the second rhIGF-I injection was given (Fig. 1). During the next
six hours serum IGF-I rose slightly further, and levels remained
at about three to four times baseline. After the last IGF-I
injection was given, at the end of the fourth day, serum IGF-I
levels began to decline but were still above baseline at the end
of study (Fig. 1). The rise and fall in the plasma IGF-I levels was
similar in both groups of subjects.
Effects of exogenous rhIGF-I on renal perfusion and
glomerular filtration
In both Group 1 and Group 2 subjects, RPF and GFR began
to rise quickly following the initial rhIGF-I injection and by the
sixth hour were clearly above baseline values (Figs. 2 and 3).
Throughout the three days of IGF-I injections, both RPF and
GFR remained elevated. There was some fluctuation in RPF
and GFR during the day; this was particularly the case for the
RPF which was usually lower during the eight hour overnight
interval and then tended to increase following the 8:05 a.m.
dose (Figs. 2 and 3). After the last injection with rhIGF-I at 8:05
a.m. on the fifth day in Groups 1 and 2, both RPF and GFR
decreased progressively toward baseline (Figs. 2 and 3).
Figure 4 depicts the grand means of the RPF and GFR for
each day of study. In Group 1, RPF rose significantly during the
A
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second day (the first day of rhIGF-I treatment; P < 0.05) and
remained elevated at about 32 4% above the baseline during
rhIGF-I treatment (Fig. 4). Similarly, GFR increased signifi-
cantly on the day that rhIGF-I treatment began (P < 0.05) and
was maintained at about 22 3% above baseline during the
three days that IGF-I injections were given (Fig. 4). In the
saline loaded subjects in Group 2 during the period of rhIGF-I
treatment, the grand means of the RPF rose by 33 2%, the
GFR rose on the first day of treatment by 19 2% and
continued to rise on the second of rhIGF-I administration to 36
3% above baseline (Fig. 4). In summary, in both groups of
subjects RPF and GFR rose quickly in response to rhIGF-I
injections and fell after stopping treatment, although values
sometimes remained above baseline on the fifth day.
The filtration fraction (FF) remained fairly constant, and the
creatinine clearance was greater than the inulin clearance in
both groups of subjects on each day of study (Table 3). The
creatinine clearance rose in parallel to the rise in GFR during
the days when rhIGF-I was administered and declined towards
baseline after the injections of rhIGF-I were stopped. The total
renal vascular resistance (RVR) during days 2 to 4, the days of
rhIGF-I treatment, was lower as compared to baseline values
and to the values obtained on day 5 (Table 3). The fall in the
I I Fig. 4. Grand means SCM of GFR and RPF
2 3 4 5 in the normal (A) and saline loaded normal
subjects (B); * < 0.05 vs. baseline.
RVR occurred within the first six hours (P < 0.05). The changes
in the RVR were inversely related to the changes in RPF.
Effects of exogenous rhIGF-I on renal tubular function and
solute handling
In the Group 1 and 2 subjects, the mean fractional excretion
of phosphate (FE04) fell markedly within the first two hours
after the initial injection of rhIGF-I (Fig. 5). During the first day
of rhIGF-I treatment the grand means of the FEB04 in Groups 1
and 2 had decreased to only 45% and 48% of baseline values,
respectively (Table 4). The FEB04 remained lower than baseline
for the remainder of the study (P < 0.05 for each group), even
during the 24 hour period after rhIGF-I treatment was discon-
tinued. The urinary phosphate excretion in Group 1 also fell
with rhIGF-I treatment and essentially remained lower than
baseline values throughout the study (Table 4). In Group 2, the
urinary excretion of P04 also fell in three out of four subjects on
days 2 through 5. The serum phosphate concentrations did not
change in either group of individuals (Table 4). In all subjects,
serum phosphate concentrations tended to be lower during the
early morning periods and somewhat higher in the afternoons.
These fluctuations throughout each day were similar during
baseline and with rhIGF-I treatment (Fig. 5).
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Table 3. Renal function data in both groups
Day 1
Baseline
Day 2
IGF-I
Day 3
IGF-I
Day 4
IGF-I
Day 5
—
Non-saline loaded subjects (Group 1)
Scr mg/dl 0.97 0.01 0.93 0.Ola 0.85 0.Ola 0.86 O.Ola 0.87 0.OP
Creatinine clearance 119 3 142 6 156 8 159 7 145 7
ml/minil.73 m2
Filtration fraction 0.24 0.01 0.23 0.01 0.21 0.Ola 0.23 0.01 0.23 0.01
GFR/RPF
Renal vascular resistance 109 7 78 3 85 a 87 5 108 5
mm Hg/minim//JO3
Saline loaded subjects (Group 2)
Scr mg/dl 0.87 0.01 0.81 0.Ola 0.72 0.Ola 0.72 0.Ola 0.73 0.0l
Creatinine clearance 134 11 162 16 181 1l 186 12 169 ioa
ml/min/1.73 m2
Filtration fraction 0.26 0.01 0.24 0.01 0.26 0.01 0.25 0.01 0.28 0.01
GFR/RPF
Renal vascular resistance 97 5 84 4 80 4 87 3 105 5
mm Hg/min/ml/JO3
Data are grand means SEM.
a P < 0.05 versus baseline
The fractional excretion of calcium (FEa) was calculated
using the total serum calcium concentrations, since measure-
ments of ionized serum calcium were not available. The frac-
tional excretion of calcium was below baseline on the first day
of rhIGF-I treatment in Group 1 (Table 4). Otherwise the FEa
did not change during the study. The absolute values for urinary
calcium excretion also remained unchanged in both groups
throughout the study.
In the Group 1 subjects, the mean fractional excretion of
sodium (FENa) was significantly lower than baseline on days 2
and 4 (Table 4). The FELl did not change significantly in Group
1 (Table 4). Those individuals that received the larger saline
load (Group 2) showed a rise in the urinary excretion of Na and
the FELl during days 3 and 4 only (P <0.05).
Renal handling of albumin and lgG
The urinary excretion of albumin and IgG, as well as the
fractional clearances of both proteins, were measured and
calculated for each clearance period. In Group 1 and Group 2,
the grand means of the fractional and the absolute excretion of
both albumin and IgG increased significantly on the first day of
treatment with rhIGF-I (Table 5, Fig. 6 A and B). Values
remained elevated above baseline throughout the period of
treatment with rhIGF-I but were lower during the 24 hour
period after the last injection. At baseline, the fractional clear-
ance of albumin, but not IgG, was lower in the Group 1 subjects
as compared to Group 2 individuals (P < 0.05), indicating that
the larger saline load given to the latter subjects may have
increased the albumin but not the IgG clearance. In no individ-
ual did the microalbuminuria exceed 20 gImin, a level that
most investigators consider well below the upper limit of
normal.
Discussion
The present study investigated the effects of three days of
subcutaneous injections of rhIGF-I on renal function. The
results indicate that treatment with rhIGF-I, 60 pg/kg subcuta-
neously three times per day, quickly elevates plasma total
IGF-I to about three to four times baseline levels and has
profound effects on certain aspects of renal function in normal
man. Renal vascular resistance (RVR) decreases, and both RPF
and GFR rise within no more than a few hours after initiation of
the rhIGF-I treatment. IGF-I also causes a marked increase in
the tubular absorption of phosphate. The urinary excretion of
albumin and IgG also increases slightly during systemic treat-
ment with IGF-I. These effects occurred at a dose of rhIGF-I
that did not cause hypoglycemia in these subjects who ingested
a normal diet in six meals and received small amounts of
glucose, 27 or 81 g/24 hrs intravenously (calculated on the basis
that 90% of glucose in the intravenous solution is anhydrous
glucose).
The present studies were performed in two groups of normal
subjects that differed in the water and NaCl load that was
infused intravenously at a constant rate throughout the study.
Since growth hormone is reported to increase NaC1 and water
retention and GFR [191, we examined whether the effect of
rhIGF-I on renal hemodynamics occurred independently of
volume expansion with saline and whether the effects of IGF-I
and saline loading were additive. Indeed, at baseline, the saline
expanded subjects in Group 2 tended to have a lower RVR
(Table 3), a higher RPF and GFR (Figs. 2, 3 and 4), a higher
creatinine clearance (Table 3), a lower serum creatinine con-
centration (Table 3) and a higher urine flow rate (Table 2). The
results indicate that in both groups, RVR, RPF and GFR
responded similarly to rhIGF-I injections (Table 3, Figs. 2 to 4).
The absolute values for RPF and GFR in the saline loaded
subjects (Group 2) during the rhIGF-I injections may have been
modestly greater.
There was some variability in the RPF and GFR data
throughout each day in both groups (Figs. 2 and 3). In general,
there was a trend towards lower values during the night as
compared to the daytime. It has been shown that there is
normally a circadian rhythm of renal perfusion and filtration
with lower values during the night [20]. In addition, in the
present study the intake of food occurred between 8:05 a.m.
and 11:30 p.m. Although the food intakes were divided into six
approximately equal meals to reduce the specific effects of
ingested protein on renal function, some fluctuating effects on
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rhIGF-I. In these animals, the fall in RVR and rise in RPF and
GFR occurred within several minutes [8]. Recently, Haylor,
Sing and El Nahas demonstrated that even relatively small
amounts of IGF-I infused intravenously into anesthetized rats
almost instantaneously lower the RVR and increase renal blood
flow as measured with a magnetic flow probe [22].Furthermore,
as was recently demonstrated by Baumann and associates,
IGF-I increases renal hemodynamics in rats at low infusion
rates that result in plasma levels below the threshold required
for stimulation of blood glucose clearance [23].
We have previously investigated the effects of IGF-I on the
individual determinants of glomerular ultrafiltration and on the
regulation of renal hemodynamics [9, 24, 25]. The results
indicate that IGF-I acutely lowers the efferent and, to a lesser
extent, the afferent arteriolar resistance, thus allowing for an
increase in nephron blood flow. This in turn contributes to the
rise in single nephron GFR which is also augmented by an
increase in the glomerular ultrafiltration coefficient. IGF-I did
not elevate the glomerular capillary pressure [9]. Moreover, the
rise in nephron flow and filtration rates in the previous studies
in rats were closely correlated and of roughly equal magnitude,
so that the renal or nephron filtration fraction did not change
significantly [9, 24, 251. In the present studies in normal men,
there was, with one brief exception, no significant change in the
filtration fraction during rhIGF-I treatment (Table 3). The one
exception was the slightly but significantly lower filtration
fraction in Group 1 on day 3, the second day of IGF-I treatment.
Hence, although estimates of the glomerular ultrafiltration
pressure and the ultrafiltration coefficient are not available in
these normal subjects, the pattern of findings is similar to that
found in rats.
One of the most dramatic findings of this study was the
sudden and marked increase in the tubular absorption of
phosphate induced by rhIGF-I. The fractional excretion of P04
fell quickly during the first day of IGF-I injections, and the
reduced values were sustained below baseline until the termi-
nation of the study (Table 4, Fig. 5). The enhanced renal tubular
reabsorption of phosphate even persisted during the 24 hours
after rhIGF-I had been discontinued. To the authors' knowl-
edge, this is the most dramatic increase in tubular phosphate
reabsorption induced by an agent that has been described in
humans. The fact that the serum phosphorus did not change
indicates that this effect cannot be due to a reduction in serum
phosphorus levels. The finding that serum phosphate did not
rise during or after IGF-I administration suggests that the
retained phosphate may have been transferred intracellularly or
into bone. Since IGF-I both promotes protein anabolism in
many soft tissues and enhances bone mineralization [26], either
effect might have prevented hyperphosphatemia in the face of
the P04 retention. Physiologically, in normal subjects the
urinary phosphate excretion follows a circadian rhythm, with
minimal excretion at about 8:00 a.m. and maximal phosphate
excretion between 8:00 p.m. and midnight [27]. This circadian
rhythm of P04 excretion is still maintained in the present
subjects except that during the IGF-I treatment the undulations
occur around a lower mean compared to baseline (Fig. 5).
The results of this study are consistent with previous findings
that growth hormone injections increase renal tubule phosphate
reabsorption in humans and experimental animals [12—141. It is
likely that IGF-I mediates the growth hormone stimulated
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Fig. S. Fractional excretion of P04 (FE04) in the normal subjects
(Group 1, A) and the saline loaded normal subjects (Group 2, B). Each
data point represents the mean for each urine collection period. Arrows
indicate rhIGF-I injections, 60 pg/kg. The shaded horizontal bar repre-
sents the weighed grand means SEM of baseline clearances.
renal function by determinants other than IGF-I may not have
been completely avoided.
The finding that exogenously administered rhIGF-I lowers
RVR and raises RPF and GFR in normal man extends the
findings of Guler et al [10, 11]. These investigators showed that
RPF and GFR rose within 72 hours after starting continuous
subcutaneous rhIGF-I infusions. The present study demon-
strates that the rise in RPF and GFR occurs quickly, no later
than by six hours rather than days after the onset of rhIGF-I
treatment. This finding demonstrates that renal hypertrophy,
which is known to occur with exogenous IGF-I treatment [21],
is not essential for the increase in renal hemodynamics and
most likely does not contribute to the early effects of rhIGF-I on
renal function. The present data are also consistent with our
previous findings in anesthetized rats that were given an intra-
venous injection followed by a twenty minute infusion of
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Table 4. Tubular handling of minerals in groups I and II
Day I
Baseline
Day 2
IGF-I
Day 3
IGF-I
Day 4
IGF-I
Day 5
—
Non-saline loaded subjects (Group 1)
FE,,-4 %
Urine P04 mg/mm
17.2 1.4
0.79 0.09
7.8 10b
0.46 010b
10.2 1.9"
0.55 Ø•Ø91
9.6 1.3"
0.54 0.13
9.4 0.9"
0.47 0.07"
Serum P04 mg/dl 3.94 0.18 3.83 0.16 3.68 0.22 3.92 0.16 4.04 0.03
FEca% 1.86 0.13 1.29 0.07' 1.48 0.12 1.94 0.12 2.03 0.17
Urine Ca mg/mm 0.25 0.07 0.21 0.06 0.21 0.04 0.29 0.08 0.31 0.10
FENa % 1.26 0.07 0.69 0.05" 1.04 0.12 0.91 0.09" 1.08 0.09
Urine Na mmol/min 0.22 0.03 0.13 001b 0.18 0.01 0.18 0.02 0.19 0.01
FELl % 28.2 2.3 22.5 2.7 26.1 2.0 25.5 2.4 23.6 1.9
Saline loaded subjects (Group 2)
FEB04 %
Urine P04 mg/mm
12.4 1.2
0.63 0.12
5.9 0.6"
0.33 008b
8.1 0.8"
0.52 0.15
8.5 08b
0.55 0.13
8.4 0.9"
0.51 0.09
[Urine P04 (mg/min)]a [0.611 [0.33] [0.41] [0.45] [0.45]
Serum P04 mg/dl 3.56 0.05 3.49 0.16 3.53 0.19 3.59 0.11 3.86 0.22
FEca % 1.14 0.13 1.12 0.10 1.05 0.09 1.32 0.14 1.27 0.15
Urine Ca mg/mm 0.15 0.06 0.17 0.06 0.17 0.04 0.21 0.06 0.19 0.07
FENa % 1.20 0.12 1.04 0.14 1.47 0.17 1.52 0.18 1.43 0.18
Urine Na mmol/min 0.23 0.03 0.23 0.04 0.36 0.04" 0.37 0.05" 0.31 0.04
FELl % 20.9 0.9 21.4 1.1 35.6 17b 27.1 1.3" 21.1 1.0
Data are grand means SEM.
a In one subject in Group 2, values for urine P04 rose on day 3 and day 4, whereas values in the remaining three subjects fell. The values in
brackets are calculated excluding this one subject.b p < 0.05 versus baseline
Table 5. Microalbuminuria and microglobulinuria (IgG)
Day 1
Baseline
Day 2
IGF-I
Day 3
IGF-I
Day 4
IGF-I
Day 5
—
Microalbuminuria p.g/min
Non-saline loaded subjects 3.6 0.3 6.3 0.6a 8.4 1.4 9.8 2.8a 6.7 1.2
Saline loaded subjects 4.9 0.3 8.3 0.4a 7.8 Q•5a 7.6 1.oa 6.7 1.1
Microglobulinuria (IgG) j.g/min
Non-saline loaded subjects 0.7 0.2 1.2 0.la 1.4 0.2a 1.5 0.2a 1.1 0.1
Saline loaded subjects 1.1 0.1 1.7 o.la 1.6 o.la 1.8 o.la 1.5 0.2
Data are grand means sEM.
a p < 0.05 versus baseline
increase in renal tubular reabsorption of phosphate [14]. In
isolated perfused rabbit proximal tubules, IGF-I directly in-
creases phosphate absorption from both basolateral and luminal
sites [121.
In spite of the sustained rise in renal fractional phosphate
absorption and the reduced absolute excretion of phosphate,
the fractional excretion of calcium fell only on day 1 in Group 1
and the renal excretion of calcium did not change. However,
the interpretation of these data is difficult; the values were
calculated using the total serum calcium, because measure-
ments of ionized serum calcium were not available. It may be
noteworthy that greater renal losses of calcium did not occur
during or after IGF-I treatment in the Group 2 subjects who
displayed a rise in urinary sodium excretion.
Treatment with growth hormone for several days has been
shown to result in sodium and water retention [10, 19, 28]. Since
growth hormone is a strong secretagogue for IGF-I, some of the
effects of growth hormone on sodium and fluid retention could
have been induced by IGF-I. On the other hand, Quigley and
Baum found in short-term experiments that IGF-I has no effect
on sodium transport in isolated-perfused tubules in vitro,
whether the peptide was presented to the luminal or basolateral
membranes [12]. The results of the present study indicate that,
in the absence of saline loading, the FENa may have fallen
transiently with rhIGF-I treatment. The decrease in the frac-
tional excretion of sodium could indicate a direct effect of IGF-I
on renal tubular sodium reabsorption. Alternatively, the fall in
FENa may reflect an adaptive response to maintain sodium
balance in the face of an increased GFR. In the saline loaded
individuals the fractional excretion of sodium rose on the third
and fourth days of rhIGF-I treatment. The FELl rose only in the
saline loaded individuals. Lithium may serve as an additional
marker for sodium absorption, particularly although not exclu-
sively, in the proximal tubule [29, 301. Hence, the transient rise
in the FELl in the saline loaded group may indicate reduced
absorption of sodium in the proximal tubules.
The finding that rhIGF-I increased urinary albumin and IgG
excretion in both groups (Table 5) cannot be explained solely by
the increase in GFR, because the fractional clearances of both
proteins also increased (Figs. 6 A and B). However, the mean
rise in albuminuria did not exceed 20 g/min in any subject and
hence was still within the normal physiologic range. The
mechanisms causing this rise in microproteinuria are unknown.
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In summary, treatment with moderate doses of subcutane-
ously administered rhIGF-I in normal and saline expanded
normal men reduces renal vascular resistance and increases
RPF and GFR. RhIGF-I quickly and strikingly increases the
tubular phosphate absorption but does not appear to have major
effects on the tubular handling of sodium, except for a transient
decrease in the fractional excretion of sodium in the nonvolume
expanded subjects. IGF-I elevates the urinary excretion of
albumin and IgG by a yet unknown mechanism.
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